Literature DB >> 7947386

Preferential overexpression of a 172Arg-->Leu mutant p53 in the mammary gland of transgenic mice results in altered lobuloalveolar development.

B Li1, N Greenberg, L C Stephens, R Meyn, D Medina, J M Rosen.   

Abstract

Regulatory sequences derived from the rat whey acidic protein gene have been used to preferentially overexpress a murine 172Arg-->Leu mutant p53 in the mammary gland of transgenic mice. Several different lines of mice expressing the 172Arg-->Leu mutant p53 displayed an impaired ability to lactate, and the mice expressing the highest levels of mutant p53 were unable to nurse their young. This failure was related to the inhibition of normal lobuloalveolar development that occurred during late pregnancy and a marked decrease in milk protein gene expression at early lactation. Interestingly, immunohistochemical analysis revealed that the mutant p53 was localized predominantly in the cytoplasm of alveolar cells. Ductal development was not overtly impaired in these mice. Expression of the 172Arg-->Leu mutant p53 resulted in radiation-induced apoptosis, and transactivation or repression of the expression of a number of genes, including mdm-2 and proliferating cell nuclear antigen, known properties of wild-type p53. The availability of lines of mice preferentially expressing specific p53 mutants in the mammary gland should facilitate evaluation of the roles of other factors, such as hormones, oncogenes and chemical carcinogens, in the etiology of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947386

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  17 in total

Review 1.  Regulation of p53 and its targets during involution of the mammary gland.

Authors:  D J Jerry; J Pinkas; C Kuperwasser; E S Dickinson; S P Naber
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-04       Impact factor: 2.673

Review 2.  Choosing a mouse model: experimental biology in context--the utility and limitations of mouse models of breast cancer.

Authors:  Alexander D Borowsky
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-09-01       Impact factor: 10.005

3.  Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors.

Authors:  Chunyan Hu; Anne Diévart; Mathieu Lupien; Ezequiel Calvo; Gilles Tremblay; Paul Jolicoeur
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

4.  neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice.

Authors:  B Li; J M Rosen; J McMenamin-Balano; W J Muller; A S Perkins
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

Review 5.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

Review 6.  The preneoplastic phenotype in murine mammary tumorigenesis.

Authors:  D Medina
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

7.  Prostate cancer in a transgenic mouse.

Authors:  N M Greenberg; F DeMayo; M J Finegold; D Medina; W D Tilley; J O Aspinall; G R Cunha; A A Donjacour; R J Matusik; J M Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

8.  Production of human surfactant protein C in milk of transgenic mice.

Authors:  Y Wei; S Yarus; N M Greenberg; J Whitsett; J M Rosen
Journal:  Transgenic Res       Date:  1995-07       Impact factor: 2.788

9.  Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model.

Authors:  S Neuenschwander; A Schwartz; T L Wood; C T Roberts; L Hennighausen; D LeRoith
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

Review 10.  Transgenic mouse models of breast cancer.

Authors:  L T Amundadottir; G Merlino; R B Dickson
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.